SiVEC Biotechnologies

Executive Summary

SiVEC Biotechnologies is a private, Tucson-based company pioneering the BactPac™ drug delivery platform, which leverages bacterial components to achieve unparalleled therapeutic precision. Founded in 2015, the company focuses on enhancing the efficacy and safety of treatments by enabling targeted delivery to specific cells or tissues. SiVEC's technology aims to address critical challenges in existing therapies, such as off-target effects and poor bioavailability, potentially revolutionizing the treatment landscape in oncology, infectious diseases, and other chronic conditions. Despite limited public information, the company's proprietary platform holds promise for improving patient outcomes and positioning SiVEC as a key player in the drug delivery sector.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial for Lead Candidate30% success
• H2 2026Strategic Partnership or Licensing Agreement with Major Pharma20% success
• H1 2026Series A Funding Round Announcement40% success